LB Pharmaceuticals Inc（LBRX）财务数据LBRXLB Pharmaceuticals Inc

Evaluating the bottom line, LB Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -75.01%, provide a clear picture of how effectively LBRX converts its operational activities into shareholder value.

In the context of the broader market, LBRX competes directly with industry leaders such as ORIC and BCAX. With a market capitalization of $1.18B, it holds a significant position in the sector. When comparing efficiency, LBRX's gross margin of N/A stands against ORIC's N/A and BCAX's N/A. Such benchmarking helps identify whether LB Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The company has experienced significant losses, with a net income of -51,603,000 USD in Q2 2026 and an EPS of -1.71, indicating ongoing financial challenges.